文献速递肝病

评估抗IL-23单克隆抗体古塞奇尤单抗在酒精相关性肝病患者中安全性和耐受性的临床试验

Clinical Trial to Assess the Safety and Tolerability of Anti-IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol-Associated Liver Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2025-02-14

本研究为1期剂量递增试验,纳入13例酒精相关性肝病患者,皮下给予古塞奇尤单抗30、70或100 mg(第1天和第29天)。最常见不良事件为高尿酸血症(13%,仅轻度)和脂肪酶升高(11%,轻至中度),无严重不良事件;70和100 mg组外周IL-17、IL-23、IL-1b和TNF-α受抑制,AUDIT-C评分随时间显著下降(6 vs 5,p=0.023)。结论认为古塞奇尤单抗至100 mg安全,可能减少炎症标志物,支持进一步2期研究。

要点

  • 古塞奇尤单抗30、70、100 mg皮下给药在酒精相关性肝病患者中至100 mg剂量安全。
  • 最常见不良事件为高尿酸血症(13%,仅轻度)和脂肪酶升高(11%,轻至中度),无严重不良事件。
  • 70和100 mg组外周IL-17、IL-23、IL-1b和TNF-α受抑制,AUDIT-C评分随时间显著下降(6 vs 5,p=0.023)。

核心结论

  • 古塞奇尤单抗在酒精相关性肝病患者中至100 mg剂量安全,可能减少炎症标志物。
  • 这些发现支持进一步开展2期研究评估古塞奇尤单抗在酒精相关性肝病中的疗效,尤其是严重表型患者。

研究设计与样本

  • 1期剂量递增研究,纳入具有≥2项DSM-5酒精使用障碍标准、显著脂肪变(MRI-PDFF ≥ 8%)且MRE < 3.63 kPa(排除晚期疾病)的患者。
  • 古塞奇尤单抗在第1天和第29天皮下给药,剂量队列为30、70或100 mg。
  • 共纳入13例患者(30 mg组3例、70 mg组3例、100 mg组7例),11例完成研究,100 mg组2例提前终止。
  • 主要终点为不良事件和剂量限制性毒性。

主要发现

  • 最常见不良事件为高尿酸血症(13%,仅轻度)和脂肪酶升高(11%,轻至中度)。
  • 无严重不良事件,肝酶无显著变化。
  • 70和100 mg组外周IL-17、IL-23、IL-1b和TNF-α受抑制。
  • 酒精消费随时间显著下降(AUDIT-C:6 [3-7] vs 5 [1-6],p = 0.023)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are no FDA-approved therapies for alcohol-associated liver disease (ALD). Preclinical studies indicate that blocking IL-23/IL-17 signalling may reverse liver injury. Guselkumab, an IL-23-specific antibody approved for psoriasis, may be beneficial for ALD. AIMS: We aimed to assess the safety and tolerability of guselkumab in patients with ALD. METHODS: This phase-1 dose-escalation study included patients with ≥ 2 DSM-5 criteria for alcohol use disorder, significant steatosis (MRI-PDFF ≥ 8%) and MRE < 3.63 kPa (to exclude advanced disease). Guselkumab was given subcutaneously on Days 1 and 29 in 30, 70 or 100 mg dose cohorts. Primary endpoints were adverse events (AEs) and dose-limiting toxicity. RESULTS: We enrolled 13 patients (three 30 mg, three 70 mg, and seven 100 mg). Eleven completed the study and two early discontinued in the 100 mg group. Of them, 77% were men, and the median age was 53 [IQR 49-61] years. The median MRI-PDFF and MRE were 18.4% [IQR 8.4%-34.0%] and 2.5 [2.2-2.6] kPa, respectively. The most frequent AEs were hyperuricemia (13%, mild only) and elevated lipase (11%, mild and moderate). There were no serious adverse events or significant variations in liver enzymes. There was a suppression of peripheral interleukin (IL)-17, IL-23, IL-1b and TNF-α in the 70 and 100 mg groups, and a significant decrease in alcohol consumption over time (AUDIT-C: 6 [3-7] vs. 5 [1-6], p = 0.023). CONCLUSIONS: Guselkumab is safe in doses up to 100 mg and may reduce inflammation markers in ALD. These findings support further phase 2 studies to evaluate the efficacy of guselkumab in ALD, particularly in patients with severe phenotypes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Diaz LA, Morris S, Dave S, et al. Clinical Trial to Assess the Safety and Tolerability of Anti-IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol-Associated Liver Disease. Aliment Pharmacol Ther. 2025. PMID: 39949265. doi:10.1111/apt.70026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。